Gut Guide · Medication side effects

Medication and the gut: when the cause sits in the pill box

Before stubborn gut symptoms are tested ever more finely, it is worth looking at the list of medicines. You change none of it yourself. But you can ask the question that is often missing in the consulting room.

SJ
Shukri Jarmoukli · Physician · Area of focus: integrative medicine · ViveCura Berlin
Four routes of action Benefit and side effect Medication timeline 29 verified sources
ViveCura BlogGut Guide › Medication and the gut

All articles in the gut cluster

Why I am writing this

When gut symptoms do not go away, the search usually continues downwards. Another test, another finding. Sometimes the answer is already on the medication chart that nobody has looked at. Not as blame. As a question that belongs early.

You have a list in your head that you have been working on for months. Wheat gone. Milk gone. Onions gone. A stool test, a breath test, an ultrasound. In between a few weeks when it was better, and then not again.

On the bedside table a packet has been lying there the whole time. Maybe a painkiller for your back. Maybe a diabetes medicine you have been taking since the spring. Maybe something for heartburn that was once meant for four weeks and is now two years old.

Many people know exactly this pattern. The gaze goes inwards, deeper, finer. It rarely goes to the bedside table.

That is no reproach to anyone. Medicines are prescribed because they are needed, and in the vast majority of cases rightly so. But they almost never sit on a sheet of paper with a date, and without a date no temporal connection can be seen.

The most important sentence in this article

You change nothing of what is written here on your own. No leaving out, no reducing, no switching on your own initiative. Every adjustment belongs in the hands of the doctor who prescribed the medicine, because they know the reason it was once started. This text is meant to help you ask a better question. It is not meant to take anything away from you.

A note of its own if you are pregnant, breastfeeding or would like to become pregnant. For pregnancy and breastfeeding, separate rules apply to almost every group named here, for painkillers of the NSAID type for example explicit regulatory restrictions from about the twentieth week of pregnancy. So say it yourself at every appointment and in every pharmacy, including for over the counter products, and change nothing on your own. The same applies to anything you give to children: separate rules apply for them, and this article describes adults.

Red flags: this belongs in medical assessment, not in self treatment
  • Blood in the stool or black, shiny tarry stool
  • Vomiting blood, or vomit that looks like coffee grounds
  • Unintended weight loss, fever, night time symptoms that wake you
  • Persistent vomiting or a new difficulty swallowing
  • A new, persistent change in bowel habit from around the age of 45 to 50
  • Pallor, weakness, breathlessness or a documented anaemia
  • Bowel cancer or an inflammatory bowel disease in the family

These signs are no occasion for self experiments and no occasion to wait. They belong in a prompt medical examination. And nothing in this article is a reason to postpone a recommended colonoscopy, gastroscopy or laboratory workup, or to replace it with something else.

What awaits you here

  • What the large Nature screening of 2018 found, and what it does not say
  • The four routes along which a medicine reaches the gut
  • NSAIDs: why the stomach is only half the story
  • Why gastric protection protects at the top and not further down
  • Metformin: bile acids, serotonin, microbiome, extended release, vitamin B12
  • Opioids: a condition of its own with its own treatment cascade
  • Why some antidepressants slow the gut and others speed it up
  • How IBS treatment uses exactly this side effect on purpose
  • Iron, magnesium, statins, acarbose, colchicine, levothyroxine
  • The medication timeline you can take to your appointment
RCT / Meta randomised or pooled Human cohort, registry, case control Guideline consensus with systematic search Lab cell culture, screening, animal model

The look that is almost always skipped

Why is this look so often left out? Not out of carelessness. But because the medication list is spread across several heads.

The back belongs to orthopaedics. The blood sugar to diabetology. The mood to psychiatry. The belly to gastroenterology. Every practice knows its part and rarely sees the sum. On top of that come the preparations that do not count as a medicine at all: the magnesium from the chemist, the iron from the internet, the antacid in the handbag.

Precisely for that reason the complete list is not an act of bureaucracy. It is the first diagnostic step that you can prepare yourself.

The German S3 guideline on irritable bowel syndrome, carried jointly by the DGVS and the DGNM, lists the medication history as a standing component of the workup for good reason Guideline [Guideline]. That is no side note. It is the acknowledgement that a considerable share of gut symptoms has an explainable external cause.

Before I test ever more finely in stubborn gut symptoms, I put the complete medication list in front of me, with start dates. Sometimes the answer can already be there and not in the next laboratory report.

My position, clinically grounded, no study evidence for this approach

And the second half of that sentence matters just as much. If the list shows something, no stopping follows from it. A conversation follows.

The difference is not formal. A medicine has a reason. A blood pressure drug keeps a blood pressure down, an antidepressant keeps a depression in check, a painkiller makes movement possible again. Anyone who deletes that on their own trades one problem for another, and the second is often bigger.

Reframe

Most people ask the question the wrong way round. They ask: which medicine is to blame?

The more useful question is: which time axis fits together? A substance that has been running unchanged for seven years rarely explains symptoms that started in March. A dose increase in February may explain them very well.

That turns a vague suspicion into a checkable observation. And a difficult conversation into a factual one.

One more word on attitude. This article is no charge against medicines. It is also no call to take fewer of them. Non steroidal anti inflammatory drugs make movement possible where otherwise nothing works. Metformin is among the best studied substances in internal medicine. Opioids are often without an alternative in severe pain. Antidepressants bring people out of states that otherwise do not end.

What is additionally true: they all have side effects, and part of that plays out in the digestive tract. Holding both thoughts at once is no contradiction. It is medicine.

And now you know why the list belongs before the next test.

What the big screening found, and what it does not say

There is a number that haunts half the internet. A quarter of all medicines damage the gut flora. The number is not invented. It is just often told wrongly.

Screening, more than 1,000 substances The laboratory finding the number comes from

A team around Lisa Maier at the European Molecular Biology Laboratory tested more than 1,000 marketed substances against 40 representative gut bacterial strains in 2018, in the test tube.

24 percent of the drugs with a human target inhibited the growth of at least one strain. Antipsychotics were overrepresented in this group. The authors themselves name a possible resistance risk as an open question.

For you this means: the number describes a petri dish. What of that arrives in a living gut with thousands of species, food, a mucus layer and an immune system is not answered by it.

Maier L, Pruteanu M, Kuhn M et al. Nature. 2018;555(7698):623-628. PMID: 29555994 · DOI: 10.1038/nature25979 [In vitro, screening, no human study]

So the honest question is: is there a counter check in humans? Yes, there are two.

Metagenomics, 41 medicines The human counter check

Arnau Vich Vila and colleagues sequenced stool samples from a population cohort and two gastroenterological cohorts and compared users with non users, expressly with correction for multiple medication.

19 of 41 medicines examined showed a signal. After the correction, four groups with the strongest associations remained: proton pump inhibitors, metformin, antibiotics and laxatives. Species composition, metabolic pathways and the resistome were affected.

For you this means: not every medicine leaves a trace, but some do so clearly. And anyone taking several at once gets a different picture than the sum of the individual cases.

Vich Vila A, Collij V, Sanna S et al. Nat Commun. 2020;11(1):362. PMID: 31953381 · DOI: 10.1038/s41467-019-14177-z [Cohort, human, metagenomics]
Two cohorts, n=2,241 What shapes the microbiome most at population level

Gwen Falony and colleagues tested 69 clinical variables against microbiome composition in two independent, deeply characterised cohorts, integrated with further data sets.

Stool consistency had the largest single effect size. The largest share of overall variance, however, was explained by medication, and it additionally influenced how other factors related to the microbiome.

For you this means: if you ask at population level what shapes the microbiome, you end up at the medicines. That is the most stable argument in this whole article.

Falony G, Joossens M, Vieira-Silva S et al. Science. 2016;352(6285):560-564. PMID: 27126039 · DOI: 10.1126/science.aad3503 [Cohort, human, cross sectional]
Honest framing

A change in the microbiome is not the same as a symptom

Between a measurable shift in the stool and what you feel in your belly lies a wide field. Many people with clear microbiome signatures have no symptoms at all. And many with severe symptoms have an unremarkable finding.

That is why the microbiome does not stand at the centre of this article but at one of four places. It is the best known route, but it is rarely the route that explains the acute symptoms. What a stool test can contribute here and where its limit lies is described in stool testing, PCR and dysbiosis diagnostics.

The system behind this article

Four routes along which a medicine reaches the gut

1. The microbiome

The composition of the residents shifts. Best documented for acid blockers, metformin, antibiotics and laxatives. Often measurable, not always noticeable.

2. The mucosa

The barrier becomes permeable, erosions and ulcers develop. Here the evidence is hardest, and here the NSAID group stands right at the front.

3. Motility

Transport becomes faster or slower. Opioids slow it through mu receptors, anticholinergic substances through the acetylcholine drive, serotonin speeds it up.

4. Absorption

Nutrients and other medicines arrive less well. Vitamin B12 during long metformin use, levothyroxine alongside calcium, iron and acid blockers.

These four routes carry the rest of the article. For every drug group the benefit comes first, then the mechanism, then the typical symptom picture, and then what has been examined in studies. In that order, every time.

And now you know why the famous number from the screening is a beginning and not a diagnosis.

NSAIDs: the stomach is only half the story

That ibuprofen and diclofenac can be hard on the stomach is well known. Less well known is that, according to the data from capsule endoscopy studies, the small intestine can be affected at least as often.

First the most important thing, so that the order is right. Non steroidal anti inflammatory drugs are one of the most useful drug groups we have. They turn a shoulder immobilised by pain into a moving one. They keep people with inflammatory rheumatic diseases going in daily life. Low dose aspirin can lower the risk of a further event after a heart attack or a stroke, and large pooled analyses support that well. None of that is up for debate here.

Because this chapter concentrates on the mucosa, the second problem area should at least be named. Painkillers of the NSAID type can also put a strain on the kidney, raise blood pressure and hold water in the body. The combination of an NSAID, a blood pressure drug of the ACE inhibitor or sartan type and a water tablet is considered particularly risky. If you take these three groups together, that belongs on the list and in the conversation, and with longer use the kidney values belong under regular control.

Mechanism

Why the small bowel mucosa suffers although the pain sits in the knee

  1. Cyclooxygenase is inhibited. That is the desired effect against pain and inflammation. Alongside it, the prostaglandins disappear that look after blood flow, mucus and repair in the mucosa.
  2. On top of that comes a direct contact effect. Inside the mucosal cells the substance disturbs the mitochondria, that is the energy supply. Without energy no cell can keep its barrier tight.
  3. The barrier becomes permeable. Bacteria from the gut lumen get contact with cells that would otherwise never see them. What a barrier disturbance means in detail is described in leaky gut, intestinal permeability and zonulin.
  4. The immune system answers. Through Toll like receptor 4 and the NLRP3 inflammasome an inflammatory cascade starts with a lot of TNF alpha. This detailed chain comes predominantly from animal models [In vivo, mouse, mechanism].
  5. Neutrophils stream in, erosions and ulcers develop. Some of them bleed. Many stay silent, and that is exactly what makes them treacherous.

The review behind this puts the prevalence of mucosal breaks in chronic users at around 50 percent. For the treatment of bleeding small bowel ulcers under NSAIDs it names a single substance with documented benefit, misoprostol, and it calls even that protection incomplete. This is a scientific statement and expressly not a recommendation. What belongs next to it: misoprostol is prescription only, and in Germany no product with this substance is currently approved for this use. Its use would therefore be off label, which requires separate medical information, an individual weighing of benefit and risk and a settled question of cost. The substance can make the uterus contract and can trigger labour. It must therefore not be used in pregnancy, and for women who can become pregnant reliable contraception belongs in the conversation. Its common side effects include, of all things, diarrhoea and abdominal cramps. No dose is given here on purpose, and whether the substance comes into question at all in an individual case is decided exclusively by the treating practice. Watanabe T, Fujiwara Y, Chan FKL. J Gastroenterol. 2020;55(5):481-495. PMID: 31865463 · DOI: 10.1007/s00535-019-01657-8 [Mechanism Review, human, mechanism parts from animal models, In vivo, mouse]

That these changes are not theory has only been known since it became possible to look through the small intestine with a swallowable camera. Before that, every endoscopy ended in the duodenum and started again in the large bowel. In between lay about five metres that nobody saw.

Case control, n=41 The number that changed the view

David Graham and colleagues performed video capsule endoscopy in 21 people with arthritis who had been taking NSAIDs daily for more than three months, plus in 20 controls without NSAIDs. Two blinded assessors judged the recordings.

Visible small bowel damage was found in 71 percent of the NSAID users and in 10 percent of the controls. In five users the findings were pronounced, with more than four erosions or large ulcers. In no control was that the case.

For you this means: in unclear abdominal symptoms the question about the tablet is no side question. It belongs at the beginning. With a caveat: the study is small and examined an arthritis population, predominantly men.

Graham DY, Opekun AR, Willingham FF, Qureshi WA. Clin Gastroenterol Hepatol. 2005;3(1):55-59. PMID: 15645405 · DOI: 10.1016/s1542-3565(04)00603-2 [Case Control, n=41, human, small]

These 71 percent do not stand alone. They stand in a row, and the row is instructive because the numbers diverge.

All numbers come from capsule endoscopy studies. They are not directly comparable, because the groups examined were composed very differently. That is exactly the lesson of the table.
Group examinedMucosal breaks in the small intestineComparison group
Chronic NSAID users with arthritis (Graham 2005, n=41)71 percent10 percent without NSAIDs
Chronic users in general (Watanabe 2020, review)around 50 percentno defined control group
Long term users of low dose aspirin (Endo 2014, n=198)57.6 percentno control group, registry cohort
Uncoated low dose aspirin in iron deficiency anaemia (Ehrhard 2013, n=75)71.4 percent12.5 percent without antithrombotic
Rheumatoid arthritis with concomitant NSAIDs (Sugimori 2008, n=28)81.3 percent33.3 percent without NSAIDs
Chinese health check population (Sun 2022, n=1,599)8.3 percent overall, 36.9 percent on aspirin6.3 percent without aspirin
Counterweight

Why the 71 percent are not your personal risk

The high numbers come from selected groups: people with arthritis, people with unexplained anaemia, people in hospitals. In a Chinese health check population of 1,599 people, a considerably less preselected group, the rate was 8.3 percent overall and 36.9 percent on aspirin.

The same work also found two risk factors that have nothing to do with tablets: obesity with an odds ratio of 2.30 and smoking with 1.85. So the medicine is not the only explanation, and it is rarely the only adjusting screw.

Sun X, Wang F, Liu J et al. J Gastroenterol Hepatol. 2022;37(8):1596-1602. PMID: 35642270 · DOI: 10.1111/jgh.15892 [Cohort, retrospective, human, large]

Capsule endoscopy, n=75 Where the damage sits, and what that reveals

A French group around Ehrhard examined 75 people with unexplained iron deficiency anaemia by capsule endoscopy, 28 of them on uncoated low dose aspirin.

Mucosal breaks were found in 71.4 percent of the aspirin group compared with 12.5 percent without an antithrombotic. The lesions lay predominantly in the first third of the small intestine, and only there was the group difference clear.

For you this means: the emphasis at the front speaks for a direct contact effect of the substance, not only for one mediated through the blood. And the combination of anaemia without a visible source plus long term aspirin is a real constellation that belongs in a workup.

Ehrhard F, Nazeyrollas P, Brixi H, Heurgue-Berlot A, Thiefin G. Eur J Gastroenterol Hepatol. 2013;25(11):1265-1272. PMID: 23873021 · DOI: 10.1097/MEG.0b013e3283640fad [Cohort, retrospective, human, small]
Cohort, n=28 COX-2 selective is no free pass in the small intestine

Sugimori and colleagues examined 28 people with rheumatoid arthritis, 16 of them with concomitant NSAIDs, 12 without.

True mucosal breaks were found in 81.3 percent with NSAIDs and in 33.3 percent without. Preferential COX-2 inhibitors were associated with breaks about as often in this group as classic NSAIDs.

For you this means two things. Even without NSAIDs the small intestine is not unremarkable in rheumatoid arthritis, the underlying disease plays a part. And the expectation that a COX-2 selective preparation is automatically gentler in the small intestine does not hold in this very small study.

Sugimori S, Watanabe T, Tabuchi M et al. Digestion. 2008;78(4):208-213. PMID: 19142000 · DOI: 10.1159/000190403 [Cohort, human, very small]

Gastric protection protects at the top. Not further down.

Now comes the part that rarely turns up in advice articles. It answers the search for a stomach friendly painkiller, and the answer is uncomfortable.

Prospective registry, n=198 Two independent risk factors, both unexpected

Endo and colleagues analysed a prospective capsule endoscopy registry from five Japanese hospitals. It included 198 people who had been taking low dose aspirin for more than three months and had previously had gastroscopy and colonoscopy.

114 of 198, that is 57.6 percent, had at least one mucosal break in the small intestine. In the multivariate analysis two factors remained independently associated: use of a proton pump inhibitor with an odds ratio of 2.04 and enteric coated aspirin with 4.05.

For you this means: the acid blocker lowers the risk in the stomach, in the small intestine it was associated with more breaks in this analysis. Stomach friendly is not the same as gut friendly.

Endo H, Sakai E, Taniguchi L et al. Gastrointest Endosc. 2014;80(5):826-834. PMID: 24830581 · DOI: 10.1016/j.gie.2014.03.024 [Cohort, prospective registry, cross sectional analysis]

And now the sentence that matters just as much as the finding. This is a cross sectional analysis. It shows a connection, not proof of a cause. People who are given an acid blocker often carry a higher risk from the outset, otherwise nobody would have prescribed it.

Please do not misread this

From this study follows no reason to stop a prescribed gastric protection. The benefit of a proton pump inhibitor in the upper digestive tract during long term NSAID therapy is well documented, and a gastric bleed is a dangerous thing. The finding belongs told so that you can ask the right question. It does not belong translated into a decision of your own.

Reframe

Most people picture the digestive tract as a single tube in which one protection protects everywhere in the same way.

It is more like a chain of four very different rooms. The stomach is acidic and has a thick mucus layer. The small intestine is neutral, thin walled and built for absorption. The large bowel is a fermenter. What protects in one room can remain without effect in the next.

That is why the question is not whether a painkiller is good or bad. The question is which room is causing symptoms right now.

In practice this means: if you take NSAIDs regularly and have abdominal symptoms, anaemia or unclear iron losses alongside, that is a constellation for a conversation. There are medical options, from checking the indication through the choice of substance to further diagnostics. Which of them fits is decided by the prescribing practice. And anyone who needs NSAIDs because of an illness does not stop them on their own.

And now you know why the question about the painkiller in gut symptoms must not stay limited to the stomach.

Acid blockers and antibiotics: brief, because they have their own articles

Two groups appear at the top of every list. Both have their own article in the ViveCura cluster, so here it stays with what the system needs.

Acid blockers. The stomach is the first barrier against everything you swallow, and less acid means that more oral bacteria arrive alive further down. In an analysis of 1,815 people from three cohorts, diversity in the stool fell under proton pump inhibitors, and oral genera such as Rothia increased clearly, which the authors place as consistent with the known higher risk of gut infections Human [Cohort, human]. Everything further, from the indication through tapering to rebound, is described in heartburn and understanding acid blockers. And if the question of too little rather than too much acid interests you: low stomach acid and betaine HCl.

Imhann F, Bonder MJ, Vich Vila A et al. Gut. 2016;65(5):740-748. PMID: 26657899 · DOI: 10.1136/gutjnl-2015-310376 [Cohort, human]

Antibiotics. Twelve healthy men received a triple combination of reserve antibiotics for four days, after which their microbiome was followed for six months. After about 1.5 months the composition was close to the starting point again, but nine species that had been present in all twelve beforehand were still missing in most after 180 days. So the big picture returns within weeks, individual residents do not, and with twelve young healthy men and high dose reserve antibiotics the study is expressly not transferable to a week of amoxicillin Human [Cohort, intervention study, human, small]. What a sensible rebuild afterwards can look like is described in the gut after antibiotics.

Palleja A, Mikkelsen KH, Forslund SK et al. Nat Microbiol. 2018;3(11):1255-1265. PMID: 30349083 · DOI: 10.1038/s41564-018-0257-9 [Cohort, intervention study, human, n=12]

One distinction before the rebuild

Not every case of diarrhoea after a course of antibiotics is a question of the gut flora. If watery diarrhoea appears during or in the weeks after antibiotics, together with fever, cramping abdominal pain or blood in the stool, an inflammation caused by the bacterium Clostridioides difficile can be behind it. It can run a severe course and needs medical treatment of its own, not a rebuild with probiotics and not waiting. In this constellation a timely medical examination including stool diagnostics belongs first, and not the question of the right preparation. What lies behind it is described in Clostridioides difficile and antibiotic colitis.

The sentence from above applies here too, and to both groups. An acid blocker has a benefit that is not argued away: it protects the upper digestive tract in reflux disease, in ulcers and under demanding concomitant medication. It is therefore not stopped on your own because of a microbiome finding, it is discussed. And an antibiotic course started for a good reason is not ended early because someone read something about the gut flora on the internet. An incompletely treated infection is the bigger problem. In both cases stopping, tapering or switching is decided by the prescribing practice.

And now you know why these two groups stand here only as signposts.

Metformin: the gut is not a side stage, it is a site of action

There is a sentence I keep reading in diabetes forums. I have got used to everything, only not to this.

What is meant is the diarrhoea. It often comes in the first weeks, often after a dose increase, and in some people it simply does not go away on its own. Along with flatulence, a metallic taste, sometimes nausea.

Again the benefit first. Metformin has been the first line medicine in type 2 diabetes for decades, with one of the broadest data foundations in all of internal medicine. The point here is not whether it should be taken. The point is why it is so often noticeable in the belly.

Mechanism

Five reasons why metformin is noticeable in the gut

  1. The gut is a main site of action in its own right. Not only the liver. In the gut mucosa glucose uptake and lactate formation rise, which increases metabolic activity directly on site.
  2. The bile acid pool in the gut lumen becomes larger. Bile acids that arrive further down draw water into the gut and speed up transport. If you want to understand the bile side more closely: bile, TUDCA and bitters.
  3. GLP-1 rises. This gut hormone is part of the desired effect and at the same time influences gastric emptying and satiety.
  4. Serotonin plays a part. The greater share of serotonin in the body sits in the gut wall and is an accelerator of the motor.
  5. The microbiome shifts, and the transporter OCT1 differs from person to person. That is the best available explanation for why the same dose knocks one person over and does not touch another at all.

McCreight LJ, Bailey CJ, Pearson ER. Diabetologia. 2016;59(3):426-435. PMID: 26780750 · DOI: 10.1007/s00125-015-3844-9 [Mechanism Review, human]

RCT, four months The microbiome shift is documented in a randomised trial

Hao Wu and colleagues randomised treatment naive people with type 2 diabetes double blind to metformin or placebo, over four months, with metagenomics before and after.

Under metformin the microbiome shifted clearly, and the same shift appeared in the placebo group when it also switched to metformin after six months. In a second step the researchers transferred stool from treated donors into germ free mice, and these mice then showed better glucose tolerance [In vivo, mouse, transfer experiment].

For you this means: the microbiome change under metformin is no assumption, it has been shown in a randomised trial. Whether it also contributes to the blood sugar effect in humans comes so far from the mouse part and has therefore not yet been carried over to people.

Wu H, Esteve E, Tremaroli V et al. Nat Med. 2017;23(7):850-858. PMID: 28530702 · DOI: 10.1038/nm.4345 [RCT, human, plus In vivo, mouse, mouse part expressly marked]

What has been examined in studies, and who decides about it

The most common question is: is there a form that is better tolerated? There are data on it, and they are thinner than the tone of some guides suggests.

RCT, n=90, weak evidence Extended release against immediate release

A Pakistani group compared three groups of 30 people with type 2 diabetes over three months: immediate release metformin, extended release metformin at the same dose and extended release metformin at half the dose.

The HbA1c reduction did not differ meaningfully in statistical terms. Side effects such as diarrhoea, flatulence and upper abdominal symptoms occurred in 40 percent under the immediate release form, and under the extended release form at the same dose in less than half of that.

For you this means: the observation fits the mechanism, and it agrees with the review according to which delayed release distributes the substance differently in the gut. Even so: 90 participants, one centre, no described blinding, no DOI assigned. That is a hint, not a basis for a decision. The decision is made by the treating practice.

Hameed M, Khan K, Salman S, Mehmood N. J Ayub Med Coll Abbottabad. 2017;29(2):225-229. PMID: 28718236 (no DOI assigned) [RCT, n=90, human, small, weak evidence]

Further adjusting screws that are customary in diabetology and are likewise decided by the prescribing practice: taking the tablet with a meal instead of before it, a slower dose build up and spreading the dose across the day. You change none of that yourself, and none of it appears here with a number, because that is a prescription and not guide content.

RCT secondary analysis, 13 years The laboratory value that belongs after years

Vanita Aroda and colleagues analysed the Diabetes Prevention Program and its follow up: 1,073 people on metformin against 1,082 on placebo, with B12 measurement after five and after 13 years.

Low or borderline B12 levels were found after five years in 19.1 against 9.5 percent and after 13 years in 20.3 against 15.6 percent. Per year of metformin the risk of B12 deficiency rose with an odds ratio of 1.13. Neuropathy was more common with low B12 under metformin.

For you this means: no reason to worry, but a value that belongs with long term use. The authors expressly consider routine checks worth considering. That is arranged by the treating practice.

Aroda VR, Edelstein SL, Goldberg RB et al. J Clin Endocrinol Metab. 2016;101(4):1754-1761. PMID: 26900641 · DOI: 10.1210/jc.2015-3754 [RCT, secondary analysis, human, large]
Reframe

Many people read persistent diarrhoea under metformin as a personal failure. I just cannot tolerate anything.

The physiological reading is friendlier. For this medicine the gut is not a side stage but an actual site of action. What you feel is the substance at its workplace. And how strongly that turns out depends among other things on a transporter you did not choose.

That changes nothing about the symptoms. It changes the question in the consulting room. A confession becomes a finding.

A reminder, because it matters especially here

Even with persistent diarrhoea the rule holds: pausing, reducing or stopping metformin is decided by the treating practice, not by you alone. The blood sugar is the reason it was started, and the reason does not disappear because the belly rebels. What can be changed and what cannot is decided by the treating practice, and it is worth raising the topic rather than sitting it out.

There is one situation, though, in which you should not wait. If diarrhoea or vomiting are so severe that you cannot drink enough, if you pass hardly any urine, feel increasingly weak, breathe deeply and rapidly or develop muscle pain, then seek medical help the same day. The reason: with a heavy loss of fluid the kidney function can deteriorate, and through that, in rare cases, a dangerous over acidification of the blood can develop, called lactic acidosis. For days like these a temporary pause is an accepted approach, but it is ordered medically and not decided on your own. And if you take metformin permanently, the kidney function belongs under regular control.

And now you know why metformin diarrhoea deserves a question of its own in the consultation.

Opioids: a condition of its own, not a footnote

There is an expectation that is almost always disappointed. The body will get used to it.

For the pain effect that is often true. For the constipation it is not.

And here too the benefit belongs first. In severe pain, after operations, in cancer treatment and in palliative care, opioids are often without a real alternative. People who can sleep and move because of them should keep them.

Mechanism

Why this brake is different from every other

  1. Mu receptors do not sit only in the brain. They also sit in the enteric nervous system, the gut wall's own nerve network.
  2. There they slow the forward drive. The propulsive waves become weaker, while the tone of individual segments rises. The content stays put for longer.
  3. In addition less fluid is secreted and more is reabsorbed. The stool becomes harder the longer it is on the way.
  4. This brake develops hardly any tolerance. While the pain effect adapts over weeks, the slowing remains, often across the whole duration of treatment.
  5. That is why it has a name of its own. Opioid induced constipation is not an unspecific constipation but a defined problem with its own treatment cascade.

The general search for causes in constipation, from the thyroid through the pelvic floor to nutrition, is described in constipation seen as a whole: the causes. Here it is exclusively about the medication route.

Longitudinal, n=489, four countries Why ordinary laxatives are often not enough

Karin Coyne and colleagues surveyed people on long term opioid therapy for chronic non cancer pain in the USA, Canada, the United Kingdom and Germany, at baseline and over 24 weeks.

489 participants at baseline. 27 percent took no laxative at all, 25 percent took too little, 48 percent took an adequate amount. Among those with adequate use, 93 percent met the criteria for an inadequate response at baseline, and over the course the share lay between 59 and 81 percent.

For you this means two things. First: that laxatives are often not enough here is no isolated case. Second: a quarter get no treatment for it at all, and that is a reason to raise the topic yourself at the next appointment.

Coyne KS, Margolis MK, Yeomans K et al. Pain Med. 2015;16(8):1551-1565. PMID: 25802051 · DOI: 10.1111/pme.12724 [Cohort, n=489, prospective survey, self report]

That a treatment logic of its own follows from this is no fringe opinion. It is written in a guideline.

Guideline, GRADE based The stepwise approach of the American professional society

The American Gastroenterological Association published a GRADE based guideline in 2019 specifically on the medical management of opioid induced constipation Guideline [Guideline].

It sets out a stepwise approach: laxatives as the first line, and in the case of an inadequate response peripherally acting mu opioid receptor antagonists, PAMORA for short. Further principles of action such as secretagogues are also covered.

For you this means: there is a recognised plan B, and it is no makeshift. Which substance suits you and whether it suits you at all is decided exclusively by the prescribing practice. Doses are not in this article, for good reason. And expressly: an opioid is not reduced, skipped or stopped on your own because of the constipation. Every change to substance, dose or timing belongs in the hands of the prescribing doctor.

Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. Gastroenterology. 2019;156(1):218-226. PMID: 30340754 · DOI: 10.1053/j.gastro.2018.07.016 [Guideline]
Two phase 3 RCTs, n=1,352 The worry almost everyone has first

William Chey and colleagues tested a peripherally acting mu antagonist against placebo in two identical double blind phase 3 trials in outpatients with non cancer pain, over twelve weeks.

Response rates were 44.4 against 29.4 percent in one and 39.7 against 29.3 percent in the other trial. Decisively: pain scores and daily opioid dose remained comparable between the groups.

For you this means: the most common worry, namely that such a treatment weakens the pain effect, did not materialise in these trials. At the same time around 29 percent also responded under placebo. The effect is real and moderate, not overwhelming. The trials were funded by the manufacturer.

What belongs here for safety: adverse events, mostly in the gastrointestinal area, occurred most frequently under the higher of the two doses tested, and the response rates quoted above come from exactly that group. These medicines are prescription only, and they are not suitable for everyone. With a known or suspected bowel obstruction, for example, they must not be given, because otherwise a perforation of the bowel wall is a risk. Which substance suits you, and whether it suits you at all, is decided exclusively by the prescribing practice.

Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. N Engl J Med. 2014;370(25):2387-2396. PMID: 24896818 · DOI: 10.1056/NEJMoa1310246 [RCT, n=1,352, phase 3, human, large]
Reframe

Many people take constipation under opioids for the price you simply pay. That is why they do not mention it at all.

But it is not a price, it is a treatable problem with a guideline of its own. And it has consequences that go far beyond inconvenience: appetite, nausea, abdominal pain, and in some people the thought of leaving the painkiller out.

Exactly that last point is dangerous. It is better to raise the constipation than to quietly undermine the pain treatment.

And now you know why this topic has earned a name of its own and a plan of its own.

Antidepressants and anticholinergic substances: the brake that works both ways

Two people take an antidepressant. One gets constipation, the other diarrhoea. Both are right. They are simply different substances.

The reason lies in two opposing systems in the gut wall. Acetylcholine is the drive of the gut muscle. Serotonin is the timekeeper that speeds the movement up. Whoever blocks acetylcholine slows things down. Whoever raises serotonin steps on the gas.

The system in one picture

Who slows down, who speeds up

Anticholinergic in effect, so rather slowing
Tricyclic antidepressants, many older antihistamines, certain bladder medicines, some Parkinson and psychiatric drugs, several remedies against nausea and cramps.
Serotonergic in effect, so rather accelerating
Selective serotonin reuptake inhibitors, particularly in the first weeks after starting or after a dose adjustment.
The point that is easy to overlook
It is rarely a single substance. It is the sum. Many medicines have anticholinergic properties although their main effect is a completely different one. This anticholinergic total burden adds up, and older people react to it more sensitively.
A good laboratory test for it does not exist. The serum anticholinergic assay is regarded as unreliable. The tool is the list.

Lampela P, Paajanen T, Hartikainen S, Huupponen R. Drugs Aging. 2015;32(12):963-974. PMID: 26518014 · DOI: 10.1007/s40266-015-0321-6 [Mechanism Review, human, qualitative, no quantification of constipation]

The twist: the same brake is the treatment elsewhere

And now comes the change of perspective that carries this section. Exactly the effect that causes an unwanted constipation in one person is the treatment principle in another.

Network meta-analysis, k=51, n=4,644 Tricyclics in irritable bowel syndrome

Christopher Black and colleagues around Alexander Ford searched the large databases up to August 2019 and pooled randomised trials on soluble fibre, antispasmodics, peppermint oil and gut brain neuromodulators in irritable bowel syndrome.

51 trials with 4,644 patients. For overall symptoms peppermint oil ranked first with a relative risk of 0.63, tricyclics second with 0.66. This relative risk describes the failure to improve, so a value below 1 speaks for the substance. For abdominal pain tricyclics came first with 0.53, though only on the basis of four trials with 92 patients. Side effects occurred more often under tricyclics than under placebo.

For you this means: the drug group that elsewhere slows the gut as a side effect is among the options with the best balance in irritable bowel syndrome with diarrhoea. With a caveat: only 13 of the 51 trials had a low risk of bias, and the abdominal pain figure rests on very few patients.

Black CJ, Yuan Y, Selinger CP et al. Lancet Gastroenterol Hepatol. 2020;5(2):117-131. PMID: 31859183 · DOI: 10.1016/S2468-1253(19)30324-3 [Meta-analysis, k=51, n=4,644, network, human]
RCT, phase 3, n=463 ATLANTIS: the largest trial on this, and it ran in general practice

Alexander Ford and colleagues randomised 463 adults with irritable bowel syndrome by Rome IV criteria and ongoing symptoms in 55 English general practices to low dose amitriptyline or placebo, over six months. In the trial the dose was adjusted according to a medically supervised protocol.

After six months the symptom score IBS-SSS was 27.0 points lower under amitriptyline than under placebo. 20 percent had discontinued in the amitriptyline group and 26 percent in the placebo group. Serious adverse events were rare in both groups and similarly distributed.

One limitation belongs with this: only people with no evidence of suicidal ideation were included in this trial. That is not a formality. Tricyclics can cause severe cardiac arrhythmias in overdose, which is why the choice of person matters here just as much as the substance. If you are in a crisis or have thoughts of taking your own life, please get help immediately: in Germany the Telefonseelsorge is available around the clock and free of charge on 0800 111 0 111 or 0800 111 0 222, in an emergency call 112.

Important for the German context: amitriptyline is a prescription only antidepressant and is not approved for irritable bowel syndrome in this country. Its use would therefore be off label, which requires separate medical information, an individual weighing of benefit and risk and a settled question of cost. Its risk profile includes dry mouth, constipation, a drop in blood pressure on standing up, effects on the heart rhythm and a reduced fitness to drive. With narrow angle glaucoma, an enlarged prostate or certain heart conditions the substance can be unsuitable.

For you this means: the effect is real and moderate, and it was shown where most people are treated. It is no promise for everyone. A dose is not given here, because that is a medical prescription.

Ford AC, Wright-Hughes A, Alderson SL et al. Lancet. 2023;402(10414):1773-1785. PMID: 37858323 · DOI: 10.1016/S0140-6736(23)01523-4 [RCT, n=463, phase 3, human, large]

Two guidelines place this. The American irritable bowel guideline of the American College of Gastroenterology from 2021 lists gut brain neuromodulators, which include the tricyclics, as a treatment option for global irritable bowel symptoms Guideline [Guideline]. The German S3 guideline on irritable bowel syndrome from the DGVS and the DGNM likewise treats neuromodulators as an option and lists the medication history as a standing component of the workup Guideline [Guideline]. What else belongs to the mechanics of irritable bowel syndrome is described in IBS: finding the causes, and a well studied non drug option is described in gut directed hypnotherapy for IBS.

The safety side that belongs with it

Meta-analysis, n=393,268 SSRIs and NSAIDs: the combination is the point

Rebecca Anglin and colleagues pooled 15 case control studies with a total of 393,268 participants and four cohort studies on the frequency of upper gastrointestinal bleeding.

For SSRIs alone the odds ratio was 1.66. For the combination of SSRI and NSAID it was 4.25. The number needed to harm was 3,177 in a low risk population and 881 in a high risk population.

For you this means: the individual risk of an SSRI stays small, and the authors themselves stress that it lies lower than previously estimated. The combination with a painkiller is nonetheless a good occasion to look at both prescriptions together once. That is no argument against SSRIs, it is an argument for a conversation.

One further combination expressly belongs here, even though it was not the subject of this meta-analysis. If you take anticoagulant medicines, that is a classic blood thinner, a direct oral anticoagulant or a second platelet inhibitor, then every additional painkiller of the NSAID type can raise the bleeding risk in the gastrointestinal tract considerably. That also applies to over the counter packs from the drawer. In this constellation, discuss every painkiller beforehand instead of adding it yourself.

Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Am J Gastroenterol. 2014;109(6):811-819. PMID: 24777151 · DOI: 10.1038/ajg.2014.82 [Meta-analysis, n=393,268, human]
Especially important with antidepressants

Stopping abruptly carries its own risks. It can trigger discontinuation symptoms, from dizziness and abnormal sensations through to sleep problems, and it can bring the underlying illness back. Both are serious. If you have gut symptoms on an antidepressant, the right route is the conversation with the prescribing practice, not leaving it out. A switch within the same drug group is also a medical decision, not self help.

And if you feel worse mentally, or if you have thoughts of taking your own life, do not wait until the next regular appointment. In Germany the Telefonseelsorge is available around the clock and free of charge on 0800 111 0 111 and 0800 111 0 222, in an emergency call 112.

Reframe

The widespread story goes: side effect equals harm, main effect equals benefit. Neatly separated.

The gut shows that this separation does not hold. The same anticholinergic brake is a troublesome constipation in one person and a recognised treatment option against abdominal pain in another. It is not the substance that decides, it is the person who receives it, and the reason.

That is why the sentence This medicine is bad for the gut rarely makes sense. The usable sentence is: this medicine has an effect on gut motility, and in your case this effect is currently unwanted.

And now you know why two people on the same medicine can have opposite experiences without either of them exaggerating.

The small overlooked ones: iron, magnesium, statins, colchicine

The big groups are now in place. But the list you bring to the appointment rarely consists only of prescription substances. It also consists of what lies in the kitchen drawer.

Iron preparations

The benefit is undisputed. An iron deficiency can make you tired and weak, can impair stamina and concentration and can affect the immune defence. Clarifying it and treating it is right.

Meta-analysis, k=43, n=6,831 How often ferrous sulfate is hard on the gut

Zoe Tolkien and colleagues pooled randomised trials in which ferrous sulfate was tested against placebo or against intravenous iron, with gastrointestinal side effects as the outcome.

43 trials with 6,831 adults. Against placebo the odds ratio was 2.32, against intravenous iron 3.05. The meta-regression found no relationship between dose and side effect rate.

For you this means two things. Symptoms under iron tablets are no isolated case but around twice as common as under placebo. And simply halving the dose was no reliable way out in this analysis. Form and route of intake counted for more.

Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. PLoS One. 2015;10(2):e0117383. PMID: 25700159 · DOI: 10.1371/journal.pone.0117383 [Meta-analysis, k=43, n=6,831, human, large]

One detail that is not printed in bold in any package leaflet and that I consider practically important: iron colours the stool black. That is harmless in itself. But it can mask true tarry stool from an upper bleed. If the stool is shiny black and sticky, if weakness, pallor, palpitations or abdominal pain come with it, that belongs in immediate medical assessment and is not attributed to the preparation.

And a second thought that belongs to the subject of this article: not every iron deficiency is a question of intake, and not every symptom under iron comes from the preparation. A so far unrecognised coeliac disease can explain both at once, the stubborn iron deficiency and the gut symptoms. With that comes the most important practical note in this field: anyone who eats gluten free on their own before the workup can make the diagnosis impossible, because antibodies and tissue findings can regress on a gluten free diet. So the order is diagnostics first, then a change of diet. How this workup proceeds is described in recognising coeliac disease.

And the sentence of this article applies here too: an iron preparation prescribed for a proven deficiency is not stopped, halved or swapped for something else on your own. What can change in preparation, dose, intake rhythm or route is decided by the prescribing practice.

More on tolerability, absorption and alternatives is described in iron tablets and their side effects, iron deficiency despite iron tablets and iron infusion against iron tablets. Why a gut problem can itself disturb iron absorption is described in iron deficiency from an absorption problem in the gut.

Magnesium and aluminium containing preparations

Magnesium salts draw water into the gut osmotically. That is why they are a classic laxative at higher doses, and why a preparation you take on your own initiative can make the stool softer. How strongly depends on the salt form and on the amount, because poorly soluble forms stay longer in the gut lumen. Aluminium containing antacids go the other way and can slow things down. Both groups have their benefit: magnesium in proven deficiency and in defined uses, antacids for rapid acid binding. So the same applies here: what a doctor prescribed you do not change yourself, and what you bought yourself still belongs on the list and in the conversation. The comparison of forms is described in which magnesium is the best.

Statins

Here too the benefit comes first. In people at raised cardiovascular risk statins can lower the risk of heart attack and stroke, and large pooled analyses support that well. That is the reason they are prescribed. Nothing in the following section questions that.

Counter observation

Not every medicine microbiome relationship runs in the unfavourable direction

Sara Vieira-Silva and colleagues examined quantitative stool metagenomes of a European cohort with 888 people, validated in two further groups with 282 and 2,345 participants.

In participants without a statin the frequency of the dysbiotic Bacteroides2 type rose from 3.90 percent in lean and overweight people to 17.73 percent in obesity. Under statin therapy it was 5.88 percent in obese participants.

That is a cross section. It shows a connection, not a cause, and the authors themselves call for a prospective study before anything therapeutic is derived from it. For the honesty of this article the finding still matters. Vieira-Silva S, Falony G, Belda E et al. Nature. 2020;581(7808):310-315. PMID: 32433607 · DOI: 10.1038/s41586-020-2269-x [Cohort, n=888, human, cross sectional]. And neither this favourable finding nor an unfavourable one would ever be a reason to stop a prescribed statin or change its dose on your own. That is decided by the prescribing practice. When a statin is up for discussion at all is placed in statins in young people.

Acarbose

Here the data are thin, and that is why no number appears here. The mechanism, by contrast, can be described clearly: acarbose slows the breakdown of complex carbohydrates in the small intestine so that blood sugar rises more slowly after a meal. What is not broken down travels further back and is fermented there by bacteria. Flatulence, rumbling and soft stool can arise from that. It is the same process you know from the FODMAP context, only triggered by a medicine. That flatter rise in blood sugar after a meal is exactly the benefit. So with acarbose too: symptoms belong in the conversation, the preparation is not left out or changed in dose on your own. How this fermentation works is described in using the FODMAP diet properly and in fibre myths [Mechanism Review, mechanistically plausible, no robust meta-analysis on frequencies verified].

Colchicine

Again the benefit first. Colchicine is an old anti-inflammatory substance with a firm place in the acute gout attack, in familial Mediterranean fever and in pericarditis. It is not prescribed without reason.

Meta-analysis, k=17, n=16,238 Diarrhoea as a known accompaniment

Xu Tian and colleagues pooled randomised trials on colchicine in which it was used for the prevention of atrial fibrillation, with safety as an outcome in its own right.

17 trials with 16,238 participants. The overall rate of side effects did not differ meaningfully, but diarrhoea, nausea and treatment discontinuation occurred clearly more often under colchicine. The authors note that these events can turn out lower with a low dose and a longer duration of use.

For you this means two things. First, diarrhoea under colchicine is common and well documented in these trials. Second, and this matters more: with colchicine, diarrhoea, nausea and vomiting are at the same time the first signs by which an overdose announces itself, and with this substance the margin between effect and poisoning is very narrow. New or increasing gastrointestinal symptoms under colchicine therefore belong reported to a doctor promptly, not endured.

You should be especially watchful if your kidney or liver values are impaired, or if certain other medicines are running at the same time, for example some antibiotics, some blood pressure or immune medicines, or a statin. These combinations can raise the colchicine level in the blood considerably, and together with a statin the risk of muscle breakdown can rise as well. Important for placing the trials: they examined atrial fibrillation, not gout. The side effect data are transferable, the indication is a different one. Dose, pause or stopping is decided exclusively by the prescribing practice, never by the gut alone.

Tian X, Zhang N, Korantzopoulos P et al. Int J Cardiol. 2024;406:132068. PMID: 38648916 · DOI: 10.1016/j.ijcard.2024.132068 [Meta-analysis, k=17, n=16,238, human, large]

Levothyroxine: not a gut problem, but an absorption problem

Levothyroxine replaces a hormone the thyroid no longer makes in sufficient amounts, and an untreated or underdosed underfunction has consequences of its own, from fatigue through weight to the heart. So the benefit is not up for debate. Levothyroxine itself does not cause gut symptoms. It suffers from them. Its absorption can be disturbed by calcium, iron, acid blockers and other preparations, and with several at once these effects add up.

Cohort, very small: n=11 When interfering factors add up

Roberto Vita and colleagues followed eleven people with apparently reduced absorption of levothyroxine tablets, in whom at least two interfering preparations were taken at the same time.

At the same daily dose and with unchanged concomitant medication, TSH values were clearly lower after a switch to a liquid formulation. Those taking three interfering preparations reached poorer values than those taking two.

For you this does not mean that a particular formulation is better. Eleven people without a control group carry no such statement. What the finding does carry is the simple question about intake intervals. And you clarify that with the prescribing practice.

Vita R, Di Bari F, Benvenga S. Expert Opin Drug Deliv. 2017;14(4):467-472. PMID: 28151692 · DOI: 10.1080/17425247.2017.1290604 [Cohort, n=11, human, very small]

If you take thyroid hormone and still have symptoms despite good values, it is worth looking at both, at the setting and at the intake situation. You do not change the dose yourself and you do not skip a dose to try something out: dose, formulation and intake intervals are decided by the prescribing practice on the basis of the values. More on that in levothyroxine and persisting symptoms. How an acid blocker can also influence iron absorption is described in acid blockers and iron absorption.

A word on microscopic colitis

There is a form of gut inflammation that can only be seen under the microscope and that causes watery diarrhoea although the colonoscopy looks unremarkable. In a Dutch case control study from a general practice database the odds for such a diagnosis were raised under proton pump inhibitors and NSAIDs, compared with colonoscopy negative controls with adjusted values of 10.6 for proton pump inhibitors and 5.6 for NSAIDs, though with very wide confidence intervals up to 64.2, and the authors place part of the remaining associations rather as an amplification of existing symptoms than as a cause Human [Case Control, wide confidence intervals]. An article of its own on this follows in this cluster. Masclee GMC, Coloma PM, Kuipers EJ, Sturkenboom MCJM. Am J Gastroenterol. 2015;110(5):749-759. PMID: 25916221 · DOI: 10.1038/ajg.2015.119.

Here too, and expressly so

These findings are no reason to stop a prescribed medicine. They are a reason to bring the complete list along in persistent watery diarrhoea and to ask the question. What follows from it is decided by the doctor, if needed with further diagnostics. A recommended colonoscopy with tissue sampling is not replaced by this article at any point.

And now you know why the over the counter preparations belong on the list as well.

The medication timeline: what you bring to the appointment

A consultation rarely lasts long. In that time someone is supposed to understand what has been happening for months. That almost never works by telling it, and it often works on a sheet of paper.

What I describe here is an approach from practice, not a validated instrument. For this specific format there is no study, and I name that expressly [Clinical practice, no study evidence for this format].

Four columns on one sheet

How you build the timeline

1
Active substance, not only the brand name

Write down both. The brand name is on the packet, the active substance underneath it or in the leaflet. Along with the dose and the time of intake. Two preparations with different names can contain the same active substance, and that only becomes visible this way.

SubstanceDoseTime of day
2
Start and change dates, as precisely as possible

This is the most important column and the one that is almost always missing. Not only the start, but also every dose increase, every change of preparation and every pause. If you no longer remember the date, a look at prescription printouts or pharmacy receipts can help.

StartIncreasePause
3
Symptom onset and course on the same time axis

Underneath, not beside. When did it start, when did it get worse, when was it better. Rough details are enough, months will do. This is not about precision, it is about both lines being readable next to each other.

OnsetWorseningbetter phases
4
What has already been tried and what happened

Changes of diet, preparations, investigations, treatments. With the date and with the result, even when the result was nothing. That prevents repetition and makes visible what is still open.

AttemptPeriodResult

Bring everything you swallow, not only the prescription items. Food supplements, laxatives, antacids from the handbag, painkillers from the drawer, herbal preparations. This group is almost always missing, and it is often the most interesting one.

What you can pack in addition

  • The medication plan. Anyone taking three or more medicines long term is entitled in Germany to a nationally standardised medication plan. The pharmacy can print it out and update it.
  • Prescription printouts or receipts from the last twelve months. They are the best source for start dates when memory is not enough.
  • All lists brought together. When several practices prescribe, the complete list often exists nowhere. Bringing it together is something only you can take on.
  • The question you would like answered. For example: does the onset of my symptoms fit in time with a change, and is there an alternative within the same drug group.
  • The red flags, if any apply. Blood in the stool, tarry stool, weight loss, fever, night time symptoms, anaemia. These belong named first, not at the end.

What does a doctor do with such a list? Four things, in this order. First, check the temporal fit, that is whether symptom onset and a medication change fit together at all. Second, check the indication, that is whether the medicine is still needed in this form. Third, consider alternatives within the same drug group or sort out intake intervals and timings. And fourth, when it is medically defensible, plan a controlled stop and restart.

The sentence that holds this article together

You change none of this yourself. The prescribing doctor decides about leaving out, switching, extended release forms, dose or timing, because they know the reason the medicine was started. Your task is the list and the question. That is no small task, and it is the one that nobody but you can take on.

The core in three sentences

In stubborn gut symptoms the complete medication list with start dates belongs at the beginning of the search for a cause and not at the end. Four routes explain most of it: microbiome, mucosa, motility, absorption. And every consequence drawn from it belongs in medical hands, because each of these medicines has a reason.

To close, once more what stands above everything. If red flags appear, that is blood in the stool, black tarry stool, vomiting blood, unintended weight loss, fever, night time symptoms or a new persistent change in bowel habit from around the age of 45 to 50, then this is not a case for a list but for a prompt appointment. And a recommended colonoscopy, gastroscopy or laboratory workup is not replaced or postponed by anything in this article.

And now you know why a sheet of paper sometimes clarifies more than the next test.

Common questions about medication and the gut

Which medicines put the most strain on the gut?

In a metagenomic analysis of 41 commonly used medicines, 19 showed a signal in the microbiome, most strongly proton pump inhibitors, metformin, antibiotics and laxatives. At the symptom level, non steroidal anti inflammatory drugs, opioids, anticholinergic substances, iron preparations, magnesium containing preparations and colchicine join the list. Which group counts for you is not decided by statistics but by your own list with start dates. And none of these substances is ever changed on your own.

Ibuprofen and the stomach: is gastric protection enough to protect the gut?

A proton pump inhibitor lowers the risk in the stomach and in the duodenum. For the small intestine that does not apply. In a prospective capsule endoscopy registry with 198 long term users of low dose aspirin, use of a proton pump inhibitor was even independently associated with more mucosal breaks, odds ratio 2.04. That is a cross sectional analysis and no proof of a cause. And it is expressly no reason to stop a prescribed gastric protection.

What does stomach friendly painkiller actually mean?

Almost always it means the combination of a non steroidal anti inflammatory drug with an acid blocker, or an enteric coating. Both aim at the stomach. In the same registry the enteric coated aspirin form was associated with an odds ratio of 4.05 for small bowel breaks, presumably because the substance is released further down. Stomach friendly is therefore not the same as gut friendly. What suits you is decided by the prescribing practice.

How do I tell whether my gut symptoms come from a medicine?

The strongest clue is temporal. Note the active substance, the dose, the start date and every dose change, and put the course of your symptoms underneath on the same time axis. If onset or worsening falls within days to a few weeks after a change, that is a usable signal. No list can prove it. But it makes the question answerable in the consulting room in the first place.

Metformin and diarrhoea: what to do when it does not stop after weeks?

First of all it belongs on the table and not endured in silence. Metformin is a well studied first line medicine, and the gut is one of its actual sites of action, which is why symptoms there are common. Several adjusting screws have been studied: the extended release preparation, taking it with a meal and a slower dose build up. All of that is decided by the treating practice, not by the package leaflet and not by this article.

Is the extended release form of metformin better tolerated?

In a small randomised trial with 90 participants, side effects under the immediate release form occurred in 40 percent, and under the extended release form at the same dose in less than half of that. The trial is small, single centre and methodologically weak, it carries no large claim. A review places the finding mechanistically, because delayed release distributes the substance differently in the gut. A switch remains a medical decision.

Do I need vitamin B12 checked during long term metformin use?

The secondary analysis of the Diabetes Prevention Program found low or borderline B12 levels after 13 years in 20.3 percent under metformin compared with 15.6 percent under placebo. Per year of use the risk rose, odds ratio 1.13. The authors consider regular checks worth considering. This is no reason to worry, it is a laboratory value you can raise at your next appointment.

Antidepressants and constipation: what can be done?

Constipation is typical for anticholinergic substances, and the tricyclic antidepressants belong to them. It makes sense to raise the topic early instead of sitting it out. Important here: stopping antidepressants abruptly carries its own risks, from discontinuation symptoms to a return of the underlying illness. Changes to substance, dose or timing therefore belong exclusively in the hands of the prescribing doctor.

Why does an SSRI tend to cause diarrhoea and a tricyclic tend to cause constipation?

Because they act on opposing controls. Serotonin speeds up gut movement, and an SSRI raises the available serotonin in the gut as well. Tricyclics additionally block muscarinic acetylcholine receptors, and acetylcholine is the drive of the gut muscle. Both observations are correct, they are simply different substances with different profiles.

Opioids and constipation: why are ordinary laxatives often not enough?

Opioids slow the gut through peripheral mu receptors in the enteric nervous system, and this brake develops hardly any tolerance. It stays while the pain effect adapts. In a survey across four countries including Germany, 93 percent of those who did use laxatives in adequate amounts still met the criteria for an inadequate response at baseline. The American professional society therefore sets out a stepwise approach in which a separate drug class comes second.

How long does the gut flora need after antibiotics to recover?

In twelve healthy men after a four day triple combination, the composition was close to the starting point again after about 1.5 months. Nine species that had been present in all of them beforehand were still missing in most after 180 days. The big picture returns within weeks, individual residents do not. The study is small and used high dose reserve antibiotics, it does not transfer one to one to a week of amoxicillin.

Can iron tablets cause constipation and black stool, and is that dangerous?

A meta-analysis of 43 trials with 6,831 adults found an odds ratio of 2.32 for gastrointestinal side effects under ferrous sulfate compared with placebo. Black stool under iron is harmless in itself. It has one catch though: it can mask true tarry stool from a bleed. If the stool is shiny black and sticky, and weakness, pallor or abdominal pain come with it, that belongs in immediate medical assessment and is not attributed to the iron.

Does my magnesium supplement affect bowel movements?

Possibly, and that is no surprise. Magnesium salts draw water into the gut osmotically, softer stool through to diarrhoea can be the result. How strongly depends on the salt form and the amount, poorly soluble forms stay longer in the gut lumen. Aluminium containing antacids go the other way and can slow things down. Both belong on the medication list, even when they are sold over the counter.

Can I simply leave out a medicine for a few days to test whether it is the culprit?

No, and there are three good reasons. First, the underlying illness can come back, from a blood pressure crisis to a flare. Second, some substances have a rebound or discontinuation effect that creates new symptoms and blurs the picture further. Third, an uncontrolled attempt rarely gives a usable result, because too many things are running at once. A planned stop and restart can make sense, but it is prepared and accompanied medically.

Do I have to take levothyroxine at a distance from other preparations?

The absorption of levothyroxine can be disturbed by calcium, iron, acid blockers and other preparations, and with several at once these effects add up. A very small cohort with eleven patients found that people taking three interfering preparations were less well controlled than those taking two. No recommendation for a particular formulation follows from that. What follows is the simple question about intake intervals, and you clarify that with the prescribing practice.

Can statins harm the microbiome?

According to the data so far, rather not. In a European cohort of 888 people with two validation groups, the dysbiotic Bacteroides2 type was found in 5.88 percent of obese participants on statin therapy and in 17.73 percent without a statin. That is a cross section and shows a connection, not a cause, and the authors themselves call for a prospective study. For the honesty of this article the finding still matters: not every relationship between a medicine and the microbiome runs in the unfavourable direction.

Where this topic connects to the rest of the body

A medicine rarely acts at one place only. It touches absorption, energy, blood formation and what you eat afterwards. These neighbouring topics belong with it.

SJ

Shukri Jarmoukli

Physician · Area of focus: integrative medicine · ViveCura Berlin

I work in my private practice at the interface of conventional medicine, functional medicine and Clinical Psychoneuroimmunology. In stubborn gut symptoms what interests me first is what is already there, before something new is added. That includes the complete medication list with start dates.

On this topic I am deliberately more reserved than you might expect from an integrative practice. No herbal preparation replaces a prescribed medicine, and no observation from a cohort study justifies stopping one on your own. This article does not replace medical advice. It is meant to help you ask the question at your next appointment that would otherwise be lost.

ViveCura, Privatpraxis Shukri Jarmoukli, Skalitzer Straße 137, 10999 Berlin

Scientific sources

  1. Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019;156(1):218-226. PMID: 30340754 · DOI: 10.1053/j.gastro.2018.07.016 [Guideline]
  2. Lacy BE, Pimentel M, Brenner DM et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44. PMID: 33315591 · DOI: 10.14309/ajg.0000000000001036 [Guideline]
  3. Layer P, Andresen V, Allescher H et al. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der DGVS und der DGNM, Juni 2021. AWMF-Registriernummer 021/016. Z Gastroenterol. 2021;59(12):1323-1415. PMID: 34891206 · DOI: 10.1055/a-1591-4794 [Guideline]
  4. Maier L, Pruteanu M, Kuhn M et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555(7698):623-628. PMID: 29555994 · DOI: 10.1038/nature25979 [In vitro, screening]
  5. Vich Vila A, Collij V, Sanna S et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11(1):362. PMID: 31953381 · DOI: 10.1038/s41467-019-14177-z [Cohort, human, metagenomics]
  6. Falony G, Joossens M, Vieira-Silva S et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560-564. PMID: 27126039 · DOI: 10.1126/science.aad3503 [Cohort, human]
  7. Imhann F, Bonder MJ, Vich Vila A et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740-748. PMID: 26657899 · DOI: 10.1136/gutjnl-2015-310376 [Cohort, human]
  8. Palleja A, Mikkelsen KH, Forslund SK et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-1265. PMID: 30349083 · DOI: 10.1038/s41564-018-0257-9 [Cohort, intervention study, human, n=12]
  9. Vieira-Silva S, Falony G, Belda E et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020;581(7808):310-315. PMID: 32433607 · DOI: 10.1038/s41586-020-2269-x [Cohort, human, cross sectional]
  10. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3(1):55-59. PMID: 15645405 · DOI: 10.1016/s1542-3565(04)00603-2 [Case Control, human, n=41]
  11. Watanabe T, Fujiwara Y, Chan FKL. Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review. J Gastroenterol. 2020;55(5):481-495. PMID: 31865463 · DOI: 10.1007/s00535-019-01657-8 [Mechanism Review, human, mechanism partly from animal models, In vivo, mouse]
  12. Endo H, Sakai E, Taniguchi L et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc. 2014;80(5):826-834. PMID: 24830581 · DOI: 10.1016/j.gie.2014.03.024 [Cohort, prospective registry, human]
  13. Ehrhard F, Nazeyrollas P, Brixi H, Heurgue-Berlot A, Thiefin G. Proximal predominance of small bowel injury associated with uncoated low-dose aspirin therapy: a video capsule study in chronic users. Eur J Gastroenterol Hepatol. 2013;25(11):1265-1272. PMID: 23873021 · DOI: 10.1097/MEG.0b013e3283640fad [Cohort, retrospective, human, n=75]
  14. Sugimori S, Watanabe T, Tabuchi M et al. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion. 2008;78(4):208-213. PMID: 19142000 · DOI: 10.1159/000190403 [Cohort, human, n=28]
  15. Sun X, Wang F, Liu J et al. Risk factors for small-intestinal mucosal breaks beyond aspirin. J Gastroenterol Hepatol. 2022;37(8):1596-1602. PMID: 35642270 · DOI: 10.1111/jgh.15892 [Cohort, retrospective, human, n=1,599]
  16. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426-435. PMID: 26780750 · DOI: 10.1007/s00125-015-3844-9 [Mechanism Review, human]
  17. Wu H, Esteve E, Tremaroli V et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23(7):850-858. PMID: 28530702 · DOI: 10.1038/nm.4345 [RCT, human, plus In vivo, mouse]
  18. Hameed M, Khan K, Salman S, Mehmood N. Dose Comparison And Side Effect Profile Of Metformin Extended Release Versus Metformin Immediate Release. J Ayub Med Coll Abbottabad. 2017;29(2):225-229. PMID: 28718236 (no DOI assigned) [RCT, human, n=90, weak evidence]
  19. Aroda VR, Edelstein SL, Goldberg RB et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-1761. PMID: 26900641 · DOI: 10.1210/jc.2015-3754 [RCT, secondary analysis, human]
  20. Coyne KS, Margolis MK, Yeomans K et al. Opioid-Induced Constipation Among Patients with Chronic Noncancer Pain in the United States, Canada, Germany, and the United Kingdom: Laxative Use, Response, and Symptom Burden Over Time. Pain Med. 2015;16(8):1551-1565. PMID: 25802051 · DOI: 10.1111/pme.12724 [Cohort, prospective survey, human]
  21. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-2396. PMID: 24896818 · DOI: 10.1056/NEJMoa1310246 [RCT, phase 3, human]
  22. Lampela P, Paajanen T, Hartikainen S, Huupponen R. Central Anticholinergic Adverse Effects and Their Measurement. Drugs Aging. 2015;32(12):963-974. PMID: 26518014 · DOI: 10.1007/s40266-015-0321-6 [Mechanism Review, human]
  23. Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, Ford AC. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117-131. PMID: 31859183 · DOI: 10.1016/S2468-1253(19)30324-3 [Meta-analysis, network, human]
  24. Ford AC, Wright-Hughes A, Alderson SL et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10414):1773-1785. PMID: 37858323 · DOI: 10.1016/S0140-6736(23)01523-4 [RCT, phase 3, human]
  25. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811-819. PMID: 24777151 · DOI: 10.1038/ajg.2014.82 [Meta-analysis, human]
  26. Tolkien Z, Stecher L, Mander AP, Pereira DIA, Powell JJ. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117383. PMID: 25700159 · DOI: 10.1371/journal.pone.0117383 [Meta-analysis, human]
  27. Tian X, Zhang N, Korantzopoulos P, Bazoukis G, Letsas KP, Tse G, Liu T. Efficacy and safety of colchicine for atrial fibrillation prevention: An updated meta-analysis of randomized controlled trials. Int J Cardiol. 2024;406:132068. PMID: 38648916 · DOI: 10.1016/j.ijcard.2024.132068 [Meta-analysis, human]
  28. Vita R, Di Bari F, Benvenga S. Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin Drug Deliv. 2017;14(4):467-472. PMID: 28151692 · DOI: 10.1080/17425247.2017.1290604 [Cohort, human, n=11]
  29. Masclee GMC, Coloma PM, Kuipers EJ, Sturkenboom MCJM. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110(5):749-759. PMID: 25916221 · DOI: 10.1038/ajg.2015.119 [Case Control, human]
Transparency on the evidence: where the data are thin
  1. The big screening is a petri dish. The often quoted number that a quarter of non antibiotic medicines inhibit gut bacteria comes from a laboratory test against 40 strains. It says nothing about what happens in a living gut, and it says even less about symptoms.
  2. The high NSAID numbers come from selected groups. 71 to 81 percent apply to people with arthritis, with rheumatoid disease or with unexplained anaemia. In a Chinese health check population the rate was 8.3 percent overall. Anyone who transfers the high numbers to themselves overestimates their risk.
  3. The finding on acid blockers in the small intestine is a cross sectional analysis. It shows a connection, not a cause, and comes from an older Japanese cohort on long term aspirin. No stopping follows from it and no recommendation against a prescribed gastric protection.
  4. The mouse part of the metformin study is an animal experiment. The better glucose tolerance after stool transfer was observed in germ free mice, not in people. The microbiome shift itself, by contrast, has been shown in a randomised trial in humans.
  5. The extended release trial is small and methodologically weak. 90 participants, one centre, no described blinding, no DOI assigned. It supports an observation, it does not justify a switch.
  6. The tricyclic figures in irritable bowel syndrome rest on a narrow base. Only 13 of 51 trials in the network meta-analysis had a low risk of bias, and the best abdominal pain figure rests on four trials with 92 patients. The authors stress this uncertainty themselves.
  7. The anticholinergic total burden is not quantified. The cited review describes constipation as a known peripheral reaction, without percentages. That is why none appear here.
  8. The figures on microscopic colitis have very wide confidence intervals, up to 64.2 for proton pump inhibitors. The case control design leaves part of the associations open, and the authors place part of them as symptom amplification.
  9. The statin finding is a cross section. The authors themselves call for a prospective study before a therapeutic statement is drawn from it. It stands here as a counterweight against one sidedness, not as a recommendation.
  10. On acarbose no frequency figure is given, deliberately. A robust meta-analysis on gastrointestinal side effects could not be verified, so the process is described mechanistically only.
  11. The colchicine data come from trials on atrial fibrillation, not from trials on gout. The side effect data are transferable, the indication is not.
  12. The medication timeline is clinical practice, not a validated instrument. For this specific format no study exists. It stands here as an approach, not as an evidence based measure.
  13. The safety notes and warnings do not come from the cited studies. The statements on lactic acidosis and kidney function under metformin, on Clostridioides difficile after antibiotics, on the early signs of a colchicine overdose and on the prescription and approval status of individual substances follow the product and prescribing information and general medical standard knowledge. They are deliberately given without study figures.
  14. What deliberately does not appear here. No personal doses, no treatment protocol, no suggestion for an alternative preparation and at no point the statement that a herbal remedy could replace a prescribed medicine. No sentence in this article is advice to change, reduce or end a medication on your own. From no section does it follow that a recommended colonoscopy, endoscopy or laboratory workup should be postponed or replaced. What I describe from my consultation is marked as an observation and is not a study result.

Have questions or want to book an appointment?

We'd be happy to advise you personally at our practice.

Book appointment